Angiosarcoma

Watchlist

(log in to enable)

Retrieved

2021-01-23

Source

Orphanet

Trials

—

Genes

KRAS, TP53, KDR, PLCG1, PTPRB, MYC, VEGFC, VEGFA, HRAS, GJA4, FLT1, COL18A1, CTNNB1, TEK, CSF3, JUN, ANGPT2, CCND1, FLT4, GJC2, PALB2, KIT, PECAM1, MDM2, CD274, PTEN, CDKN2A, CIC, CAMTA1, POT1

KRAS, TP53, KDR, PLCG1, PTPRB, MYC, VEGFC, VEGFA, HRAS, GJA4, FLT1, COL18A1, CTNNB1, TEK, CSF3, JUN, ANGPT2, CCND1, FLT4, GJC2, PALB2, KIT, PECAM1, MDM2, CD274, PTEN, CDKN2A, CIC, CAMTA1, POT1, PIK3CA, NOTCH1, HIF1A, DLC1, ERG, AKT1, PROX1, YAP1, SFRP2, RAF1, RET, CD34, MIR497, TIE1, VWF, BRAF, XPC, TNFAIP3, TFE3, THBS1, EFS, CDK2AP2, VHL, TYMS, TYR, SLC7A5, MAML1, ROCK2, WNT1, WT1, CD163, ADAM19, ADRB1, SIRT1, DRAP1, SUB1, H3P8, LOC110806263, RN7SL263P, MIR483, MIR378A, MIR342, MIR340, MIR17HG, MIR222, MIR214, MIR210, MIR126, MIR122, CEP85L, UBASH3B, ERRFI1, RTEL1, EMCN, SF3B6, SIRT7, PRRX2, SLC43A3, LAMTOR2, LAT, WWTR1, SMUG1, DICER1, NUP160, RPP14, TERT, ROCK1, PRDX2, HSP90AA1, HGF, MTOR, FLII, FLI1, EWSR1, ETS1, ERBB2, EPO, SLC29A1, ENG, EFNA3, S1PR1, E2F3, DCN, DAXX, CTLA4, CCN2, CRKL, CLDN4, COX8A, COPA, CHGA, CDKN2C, CDK6, TNFRSF8, BRCA2, ANXA6, ANXA2, ALK, ERAS, ICAM1, SYP, CXCL10, SOX10, SMARCB1, SLC3A2, SLC2A1, SLC1A2, CCL7, S100B, S100A9, S100A1, RPS6, ROS1, ADRB2, MAP2K7, MAPK1, PRKCI, PPARA, PIK3CG, PIK3CD, PIK3CB, PDK1, SERPINE1, NRAS, NOTCH2, NOS3, MMP1, MITF, MFGE8, MET, SMAD2, H3P10

Drugs

(-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4-(1H-indol-3-yl) pyrrolidine-2, 5-dione, (1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate, 16-base single-stranded peptide nucleic acid oligonucleotide linked to a 7-amino acid peptide, 18-(p-(, 4-oxo-4H-chromene-2-carboxylic acid (2-(2-4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl)-amide, 7-ethyl-10-hydroxy-camptothecin, Anlotinib, Autologous CD4+ and CD8+ T cells transduced with a lentiviral vector encoding an affinity enhanced T cell receptor specific to MAGE-A4, Autologous CD4+ and CD8+ T cells transduced with lentiviral vector containing an affinity-enhanced T-cell receptor targeting the New York esophageal antigen-1, Brostallicin, Camsirubicin, Crenolanib besylate, Deforolimus, Doxorubicin hydrochloride (liposomal) ( DOXIL ), Doxorubicin(6-maleimidocaproyl)hydrazone, Fenretinide, Fibromun, Genetically modified serotype 5/3 adenovirus coding for granulocyte-macrophage colony-stimulating factor, Human/murine chimeric monoclonal antibody against endoglin, Larotrectinib ( VITRAKVI ), Mammalian target of rapamcyin (mTOR) inhibitor, N-acetylsarcosyl-glycyl-L-valyl-D-allo-isoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-L-prolyl-N-ethylamide, Olaratumab ( LARTRUVO ), Ombrabulin, Paclitaxel ( TAXOL ), Palifosfamide, Propranolol hydrochloride ( HEMANGEOL ), Sindbis virus envelope pseudotyped lentiviral vector encoding New York oesophageal squamous cell carcinoma-1 protein, Trabectedin ( YONDELIS ), Vinorelbine tartrate, Yttrium (90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10

Interested in hearing about new therapies?

A rare vascular tumor characterized by a malignant space-occupying lesion composed of cells variably recapitulating features of normal endothelium. It mostly develops as a cutaneous tumor and is much less frequently located in the deep soft tissue. Clinical presentation is an enlarging mass, sometimes with symptoms like coagulopathy, anemia, persistent hematoma, or bruisability. Some tumors are associated with pre-existing conditions, e. g. Klippel-Trenaunay syndrome, Maffucci syndrome, or following radiation, among others. Older age, retroperitoneal location, large size, and high mitotic activity are predictors for poor outcome.